Behavioural and functional characterization of K(v)10.1 (Eag1) knockout mice

2013 | journal article. A publication with affiliation to the University of Göttingen.

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Behavioural and functional characterization of K(v)10.1 (Eag1) knockout mice​
Ufartes, R.; Schneider, T.; Mortensen, L. S.; de Juan Romero, C.; Hentrich, K.; Knoetgen, H. & Beilinson, V. et al.​ (2013) 
Human Molecular Genetics22(11) pp. 2247​-2262​.​ DOI: 

Documents & Media


GRO License GRO License


Ufartes, Roser; Schneider, Tomasz; Mortensen, Lena Suenke; de Juan Romero, Camino; Hentrich, Klaus; Knoetgen, Hendrik; Beilinson, Vadim; Möbius, Wiebke ; Tarabykin, Victor; Alves, Frauke ; Pardo, Luis A.; Rawlins, J. Nicholas P.; Stühmer, Walter 
K(v)10.1 (Eag1), member of the K(v)10 family of voltage-gated potassium channels, is preferentially expressed in adult brain. The aim of the present study was to unravel the functional role of K(v)10.1 in the brain by generating knockout mice, where the voltage sensor and pore region of K(v)10.1 were removed to render non-functional proteins through deletion of exon 7 of the KCNH1 gene using the '3 Lox P strategy'. K(v)10.1-deficient mice show no obvious alterations during embryogenesis and develop normally to adulthood; cortex, hippocampus and cerebellum appear anatomically normal. Other tests, including general health screen, sensorimotor functioning and gating, anxiety, social behaviour, learning and memory did not show any functional aberrations in K(v)10.1 null mice. K(v)10.1 null mice display mild hyperactivity and longer-lasting haloperidol-induced catalepsy, but there was no difference between genotypes in amphetamine sensitization and withdrawal, reactivity to apomorphine and haloperidol in the prepulse inhibition tests or to antidepressants in the haloperidol-induced catalepsy. Furthermore, electrical properties of K(v)10.1 in cerebellar Purkinje cells did not show any difference between genotypes. Bearing in mind that K(v)10.1 is overexpressed in over 70 of all human tumours and that its inhibition leads to a reduced tumour cell proliferation, the fact that deletion of K(v)10.1 does not show a marked phenotype is a prerequisite for utilizing K(v)10.1 blocking and/or reduction techniques, such as siRNA, to treat cancer.
Issue Date
Human Molecular Genetics 
Max Planck Society



Social Media